A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2022-09-02
Adverse events
Grade 1 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-11-07 (study day 57); relationship: Y
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-20 (study day 131); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-03-31 (study day 201); relationship: not assessed
Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-04-23 (study day 224); relationship: N; serious criteria: life-threatening
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-02 (study day 386); relationship: not assessed
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-11-01 (study day 416); relationship: N; serious criteria: hospitalization
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-11-01 (study day 416); relationship: not assessed
Grade 4 Asthenia — outcome: RECOVERED/RESOLVED; onset 2024-03-18 (study day 554); relationship: N; serious criteria: life-threatening
Data queries
No data queries.